ReviewAIDS (London, England)2026
Occult hepatitis B and risk of reactivation following switch to non-hepatitis B virus-active antiretroviral therapy in people with HIV.
Review in AIDS (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Occult hepatitis B infection (OBI), defined by the persistence of replication-competent hepatitis B virus (HBV) DNA in the liver in the absence of detectable hepatitis B surface antigen (HBsAg), represents a clinically relevant condition among people with HIV (PWH). The long-term persistence of covalently closed circular DNA within hepatocytes provides the biological basis for potential HBV reactivation, particularly after discontinuations of HBV-active antiretrovirals. In recent years, the increasing use of tenofovir-sparing and lamivudine-sparing antiretroviral strategies, including dual and long-acting injectable regimens, has renewed concerns regarding this risk in individuals with serological evidence of prior exposure. We performed a narrative review to summarize current evidence on the epidemiology, biological mechanisms, and clinical relevance of OBI in PWH, with a focus on HBV reactivation following antiretroviral treatment (ART) switches. Evidence from case reports, observational cohorts, and randomized switch trials was examined. Available evidence indicates that HBV reactivation after withdrawal of HBV-active antiretrovirals in HBsAg-negative, antihepatitis B core antibody-positive PWH is a real but infrequent event. Reactivation appears to cluster in specific contexts, including advanced or poorly controlled HIV infection, absence of protective anti-HBs antibodies and a history of HBsAg loss during antiviral treatment. In contrast, in individuals with sustained HIV virological suppression, preserved CD4+ cell counts, and markers of effective immune control, the absolute risk of clinically significant reactivation is low. These findings support a risk-based approach to antiretroviral simplification incorporating HBV serological history, vaccination status, and postswitch monitoring, rather than uniform restrictions on treatment switches in PWH with resolved HBV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.